The Role of Nuclear Medicine the Evaluation of Pancreatic Disease
Authors:
- Rashid A. FawwazRFRashid A. Fawwaz
- 1 April 2001
- journal article
- review article
- Published by Elsevier in Surgical Clinics of North America
- Vol. 81 (2) , 345-358
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Evaluation of Pancreatic Islet Cell Tumors by Fluorine-18 Fluorodeoxyglucose Positron Emission TomographyClinical Nuclear Medicine, 2000
- 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinomaCancer, 1997
- Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analoguesSeminars in Nuclear Medicine, 1995
- Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.Journal of Clinical Investigation, 1994
- In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsLife Sciences, 1991
- Increased expression of glycolysis‐associated genes in oncogene‐transformed and growth‐accelerated statesMolecular Carcinogenesis, 1989
- SomatostatinNew England Journal of Medicine, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEMJournal of Experimental Medicine, 1965
- On the Origin of Cancer CellsScience, 1956